Eton Pharmaceuticals (ETON) reported Thursday Q2 adjusted earnings of $0.43 per diluted share, up from $0.03 a year earlier.
Two analysts polled by FactSet expected $0.19.
Revenue for the quarter ended June 30 was $37.6 million, up from $18.9 million a year ago.
Four analysts expected $27.1 million.
The company now expects 2026 revenue to exceed $145 million, up from previous guidance of more than $120 million. Four analysts expect $121.3 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments